Germline variants analysis of Chinese breast cancer patients reveals numerous alterations in homologous recombination genes.

IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-04-01 DOI:10.1080/20565623.2025.2458432
Zhaoyun Jiang, Bing Xu, Bo Sun, Beibei Yang, Su Lu, Mengjian Li, Juan Zhang, Liqiang Qi, Qixi Wu
{"title":"Germline variants analysis of Chinese breast cancer patients reveals numerous alterations in homologous recombination genes.","authors":"Zhaoyun Jiang, Bing Xu, Bo Sun, Beibei Yang, Su Lu, Mengjian Li, Juan Zhang, Liqiang Qi, Qixi Wu","doi":"10.1080/20565623.2025.2458432","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to identify the pathogenic variants of homologous recombination (HR) genes and analyze the correlation between the pathogenic variants and clinical characteristics in Chinese breast cancer patients.</p><p><strong>Methods: </strong>A cohort of 178 breast cancer patients participated in this study. We assessed genomic alterations using a 23-gene panel, which includes most of the HR-related genes and DNA mismatch repair (MMR) gene, through next-generation sequencing. The pathogenicity of variants was determined based on the American College of Medical Genetics and Genomics standards and guidelines. The correlation between these pathogenic variants and the clinical characteristics of the patients was investigated.</p><p><strong>Results: </strong>26 pathogenic variants, including one novel suspected pathogenic variant, were detected in 28 (15.7%) patients. These variants occurred in 7 HR-related genes: <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, <i>RAD51D</i>, <i>RAD50</i>, <i>BRIP1,</i> and <i>ATM</i>. The frequency of <i>BRCA1</i> variants was higher in the younger group (8.9%) compared to the older group (2.6%), while the trend was reversed for <i>BRCA2</i> (3.0% vs. 7.8%). All three patients with the pathogenic variant (p.Lys91fs) in <i>RAD51D</i> were diagnosed with triple-negative breast cancer.</p><p><strong>Conclusions: </strong>HR-gene testing in breast cancer could help to find new suspected pathogenic variants and increase the clinical benefit of multi-gene testing for breast cancer.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2458432"},"PeriodicalIF":2.4000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Science OA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20565623.2025.2458432","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: We aimed to identify the pathogenic variants of homologous recombination (HR) genes and analyze the correlation between the pathogenic variants and clinical characteristics in Chinese breast cancer patients.

Methods: A cohort of 178 breast cancer patients participated in this study. We assessed genomic alterations using a 23-gene panel, which includes most of the HR-related genes and DNA mismatch repair (MMR) gene, through next-generation sequencing. The pathogenicity of variants was determined based on the American College of Medical Genetics and Genomics standards and guidelines. The correlation between these pathogenic variants and the clinical characteristics of the patients was investigated.

Results: 26 pathogenic variants, including one novel suspected pathogenic variant, were detected in 28 (15.7%) patients. These variants occurred in 7 HR-related genes: BRCA1, BRCA2, PALB2, RAD51D, RAD50, BRIP1, and ATM. The frequency of BRCA1 variants was higher in the younger group (8.9%) compared to the older group (2.6%), while the trend was reversed for BRCA2 (3.0% vs. 7.8%). All three patients with the pathogenic variant (p.Lys91fs) in RAD51D were diagnosed with triple-negative breast cancer.

Conclusions: HR-gene testing in breast cancer could help to find new suspected pathogenic variants and increase the clinical benefit of multi-gene testing for breast cancer.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Future Science OA
Future Science OA MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
5.00
自引率
4.00%
发文量
48
审稿时长
13 weeks
期刊介绍: Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信